Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Sino Biopharmaceu...

Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF)

Austal ( ($AU:ASB) ) has shared an update. Austal Limited has disclosed a change in director Susan Murphy’s interests, reporting the issue of 4,260...

Austal Issues Share Rights to Director Susan Murphy as Part of Fees

Austal ( ($AU:ASB) ) has provided an announcement. Austal Limited has reported a change in the interests of director Lee Goddard following the issu...

Austal Updates Market on Director Lee Goddard’s New Share Rights

An announcement from Austal ( ($AU:ASB) ) is now available. Austal Limited has reported a change in the interests of director Brent Cubis, reflecti...

Austal Updates Director Equity Interests Through Fee-Linked Share Rights

Analysts fell to the sidelines weighing in on Austal (AUTLF) and Transurban Group (TRAUF) with neutral ratings, indicating that the experts are nei...

Analysts Offer Insights on Industrial Goods Companies: Austal (OtherAUTLF) and Transurban Group (OtherTRAUF)

Autolus Therapeutics ( ($AUTL) ) just unveiled an announcement. On June 29, 2026, Autolus Therapeutics held its 2026 Annual General Meeting of shar...

Autolus shareholders approve 2025 accounts and board slate

The latest announcement is out from Austal ( ($AU:ASB) ). State Street Corporation, through several asset management and trust subsidiaries, has ce...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUTL	$1.40	-3.12%	682.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUTL	$1.40	-3.1%	682.13K
3
4
5
6

AUTL

AUTL

Get Autolus Therapeutics plc Data in Excel

Get Autolus Therapeutics plc Data in Excel